Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company's global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models.

The companies began working together starting in Q1 2025 as part of a multi-year partnership set to drive value for scientists by streamlining hundreds of R&D processes and methodologies across the globe. The focus of the partnership is to augment and accelerate the work of Kenvue's global workforce of scientists with Albert Invent's end-to-end AI platform, with the goal of simplifying processes to gain efficiencies both inside and outside of the lab and allowing these incredible scientists to meet evolving consumer needs with even greater impact.